Liminatus Pharma (LIMN) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Liminatus Pharma (LIMN).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|
Operating Expenses | ||||||
Research And Development | 400K | - | - | 1.61M (+347.22%) | 360K | - |
Selling General And Administrative | 700K (-20.45%) | 880K (+25.71%) | 700K (+169.23%) | 260K (+36.84%) | 190K | - |
Operating Expenses | 1.10M (+25.00%) | 880K (+25.71%) | 700K (-62.77%) | 1.88M (+248.15%) | 540K | - |
Operating Income | ||||||
Operating Income | -1.10M (-4.35%) | -1.15M (+64.29%) | -700.00K (-62.77%) | -1.88M (+248.15%) | -540.00K | - |
Ebit | -1.10M (-4.35%) | -1.15M (+64.29%) | -700.00K (-62.77%) | -1.88M (+248.15%) | -540.00K | - |
EBITDA | -1.10M (-24.14%) | -1.45M (-19.44%) | -1.80M (+2900.00%) | -60.00K (-88.24%) | -510.00K (-70.86%) | -1.75M |
Other Income / Expenses | ||||||
Interest Income | - | - | - | 60K (+100.00%) | 30K | - |
Interest Expense | 20K (0.00%) | 20K (0.00%) | 20K (-88.24%) | 170K (+88.89%) | 90K | - |
Net Interest Income | - | - | - | 60K (+100.00%) | 30K | - |
Other Non Operating Income | -20.00K (-99.72%) | -7.24M (+546.43%) | -1.12M (+409.09%) | -220.00K (+266.67%) | -60.00K | - |
Net Income | ||||||
Net Income From Continuing Operations | -1.12M (-86.82%) | -8.50M (+367.03%) | -1.82M (+691.30%) | -230.00K (-61.67%) | -600.00K (-65.71%) | -1.75M |
Net Income | -1.12M (-86.82%) | -8.50M (+367.03%) | -1.82M (+691.30%) | -230.00K (-61.67%) | -600.00K (-65.71%) | -1.75M |